(19)
(11) EP 4 227 321 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
27.09.2023 Bulletin 2023/39

(43) Date of publication:
16.08.2023 Bulletin 2023/33

(21) Application number: 22156205.1

(22) Date of filing: 10.02.2022
(51) International Patent Classification (IPC): 
C07K 16/30(2006.01)
A61P 35/02(2006.01)
 A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/3061; A61K 2039/505; A61K 39/39566; A61P 35/02; C07K 2317/56
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: AVA Lifescience GmbH
79211 Denzlingen (DE)

(72) Inventor:
  • DÜHREN-VON MINDEN, Marcus
    79379 Müllheim (DE)

(74) Representative: Cacace, Sabrina Rosella 
Immentalstraße 38
79104 Freiburg
79104 Freiburg (DE)

   


(54) ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF


(57) The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21R110).
The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.